TNGX - Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | Benzinga
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023 in Boston, Massachusetts.
Abstracts accepted for poster presentation
Title: MTA-cooperative PRMT5 inhibitors selectively modulate RNA splicing in MTAP-deleted cancer cells across histologies
Poster #: B018
Presenter: Matthew R. Tonini, Senior Scientist, Tango Therapeutics
Date and Time: Friday, October 13; 12:30 p.m. – 4:00 p.m.
Title: Unbiased in vitro and in vivo drug anchor screens identify mechanisms of resistance and sensitization for MTA-cooperative PRMT5 inhibitors in MTAP-deleted cancer models
Poster #: B098
Presenter: Steven Lombardo, Scientist, Tango Therapeutics
Date and Time: Friday, October 13; 12:30 p.m. – 4:00 p.m.
Title: TNG348, a selective USP1 inhibitor, shows strong preclinical combination activity with PARP inhibitors and other agents targeting DNA repair
Poster #: B054
Presenter: Antoine Simoneau, Senior Scientist, Tango Therapeutics
Date and Time: Friday, October 13; 12:30 p.m. – 4:00 p.m.
Title: Cancer-specific AI identifies multi-modal biomarkers of therapeutic response for 1,951 drugs including TNG348, a highly selective USP1 inhibitor
Poster #: B139
Presenter: Maxwell Sherman, Ph.D., Co-Founder and CSO, Serinus Biosciences
Date and Time: Friday, October 13; 12:30 p.m. – 4:00 p.m.
Title: Inducible activation of sgRNA libraries in tumor xenografts empowers large-scale in vivo target discovery screens
Poster #: C048
Presenter: Silvia Fenoglio, Principal Scientist, Tango Therapeutics
Date and Time: Saturday, October 14; 12:30 p.m. – 4:00 p.m.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements ...